Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients willing and able to provide voluntary written informed consent and to follow the protocol specific requirements.~* Male or female patients over 18 years old.~* Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected within 7 days prior to enrollment) who are admitted or being admitted to the hospital for a primary diagnosis of COVID-19.~* In the case of female patients of child-bearing potential, a negative blood pregnancy test prior to beginning the therapy.~* Patients intended to be hospitalized to receive SOC including dexamethasone treatment for COVID-19.~Exclusion Criteria:~Exclusion Criteria:~* Patients with evidence of other serious infections.~* Malignancy.~* Background disease which, in the opinion of the investigator prevents the patient from participating in the study such as:~  * Presence of serious chronic infectious.~ * A condition resulting in immunodeficiency.~ * Participants with glucose levels upon admission ≥ 250 mg/dL~ * Acute psychosis~* Patients in a critical stage of COVID-19 disease that require mechanical ventilation.~* Pregnant and lactating women.~* Patients that are currently or have participated in other clinical studies with investigational drug, biological agent, or device within 1 month or within 5 half-lives (of the drug/biologic) prior to enrollment (whichever is longer).~* Patient currently receiving chemotherapy or immunosuppressive agents not including dexamethasone within 30 days before the screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID-19 Patients (Type: EXPERIMENTAL): Moderate to severe COVID-19 patients receiving SOC and '005.
- Control (Type: PLACEBO_COMPARATOR): Moderate to severe COVID-19 patients receiving SOC and placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).